Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

Goddard, J; Castle, J; Southworth, E; Fletcher, A; Crosier, S; Martin-Guerrero, I; Garcia-Ariza, M; Navajas, A; Masliah-Planchon, J; Bourdeaut, F; Dufour, C; Ayrault, O; Goschzik, T; Pietsch, T; Sill, M; Pfister, SM; Rutkowski, S; Richardson, S; Hill, RM; Williamson, D; Bailey, S; Schwalbe, EC; Clifford, SC; Hicks, D

Clifford, SC; Hicks, D (通讯作者)，Newcastle Univ, Wolfson Childhood Canc Res Ctr, Newcastle Univ Ctr Canc, Translat & Clin Res Inst, Newcastle Upon Tyne, England.

ACTA NEUROPATHOLOGICA, 2023; 145 (5): 651

Abstract

Group 4 tumours (MBGrp4) represent the majority of non-WNT/non-SHH medulloblastomas. Their clinical course is poorly predicted by current risk-factors......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索